Plasma tau and neurodegenerative markers as predictors of rate of AD progression

血浆 tau 蛋白和神经退行性标记物作为 AD 进展率的预测因子

基本信息

批准号：
10184985
负责人：
JASMEER P CHHATWAL
金额：
$ 86.52万
依托单位：
MASSACHUSETTS GENERAL HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-30 至 2026-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10184985
关键词：
Affect Alzheimer&apos s Disease Alzheimer&apos s disease diagnosis Alzheimer&apos s disease pathology Alzheimer&apos s disease related dementia Alzheimer’s disease biomarker American Amyloid Biological Markers Blood Clinic Clinical Clinical Research Cognition Cognitive Cross-Sectional Studies Data Dementia Diagnosis Diagnostic Disease Progression Family Family Caregiver Family health status Funding Healthcare Healthcare Systems Hippocampus (Brain)Image Immunoassay Impaired cognition Impairment Light Magnetic Resonance Imaging Measures Medical Memory Loss Modeling N-terminal Nerve Degeneration Neurology Participant Pathologic Pathology Patients Performance Plasma Population Positron-Emission Tomography Public Health Research Personnel Risk Sampling Signal Transduction Spinal Puncture Standardization Syndrome Time Uncertainty amyloid precursor protein processing base blood-based biomarker clinical Diagnosis clinical care clinical diagnostics clinical predictors cognitive performance cost design flexibility formycin triphosphate functional decline gamma secretase imaging biomarker improved in vivo neurofilament neuroimaging novel predictive marker prognostic model prospective relative cost research study risk stratification tau Proteins tau aggregation tau-1 tool β-amyloid burden

项目摘要

Project Abstract: Alzheimer's disease and related dementias (ADRD) affect tens of millions of people around the world and represent a staggering challenge for patients, families, and healthcare systems. For some who present with mild levels of cognitive impairment, there is rapid worsening of cognition and function, whereas for others, the rate of progression can be absent or much slower. Understanding this variability in rate of progression is critically important to patients, families, and clinical researchers alike, and is not well-predicted by common, clinically available biomarker tools. Blood-based markers of AD pathology and neurodegeneration have potential for widespread use in clinical research and even clinical care, due to their non-invasiveness, cost relative to neuroimaging, and lack of medical contraindications to limit their use. Here we examine a set of newly developed, blood-based AD biomarkers (including neurofilament light chain, phospho-tau species, tau, and Ab fragments) that may fill this gap. Leveraging prospectively acquired samples from a large clinic population and from local clinical research studies, we will determine how these plasma measures relate to variable rates of "real-world" cognitive and functional decline, as well as to imaging-based measures of neurodegeneration and AD pathologic progression.

项目摘要：阿尔茨海默氏病和相关痴呆症 (ADRD) 影响着全世界数以千万计的人，对患者、家庭和医疗保健系统来说是一个巨大的挑战。对于一些出席的人对于轻度认知障碍，认知和功能会迅速恶化，而对于其他人来说，进展速度可能不存在或慢得多。了解进展率的这种变异性是对于患者、家庭和临床研究人员来说至关重要，并且常见的情况无法很好地预测，临床可用的生物标志物工具。 AD 病理学和神经退行性变的血液标记物由于其非侵入性、成本低，在临床研究甚至临床护理中广泛使用的潜力相对于神经影像学，并且缺乏限制其使用的医学禁忌症。在这里我们检查一组新开发的基于血液的 AD 生物标志物（包括神经丝轻链、磷酸化 tau 物种、tau、和抗体片段）可能会填补这一空白。利用从大型诊所前瞻性获取的样本人口和当地临床研究，我们将确定这些血浆测量与 “现实世界”认知和功能下降的可变速率，以及基于成像的测量神经变性和 AD 病理进展。